参考文献/References:
[1] Ying G,Cheng Y,Pi SL,et al.The role of P2Y12 receptor in ischemic stroke of atherosclerotic origin[J].Cellular and Molecular Life Sciences,2019,76(2):341-354.
[2] Rudijanto A.The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis[J].Acta Med Indones,2007,39(2):86-93.
[3] Neumann J,Riek-Burchardt M,Herz JA,et al.Very-late-antigen-4(VLA-4)-mediated brain invasion by neutrophils leads to interactions with microglia, increased ischemic injury and impaired behavior in experimental stroke[J].Acta Neuropathol,2015,129(2):259-277.
[4] Zeymer U,Cully M,Hochadel M.Adherence to dual antiplatelet therapy with ticagrelor in patients with acute coronary syndromes treated with percutaneous coronary intervention in real Life. Results of the REAL-TICA registry[J].European Heart Journal-Cardiovascular Pharmacotherapy,2018,4(4):205-210.
[5] Harada K,Matsumoto Y,Umemura K.Adenosine diphosphate receptor P2Y12-Mediated migration of host smooth Muscle-Like cells and leukocytes in the development of transplant arteriosclerosis[J].Transplantation,2011,92(2):148-154.
[6] Chen Z,Di Z,Li GZ.The role of microglia in viral encephalitis: a review[J].J Neuroinflammation,2019,16(1):76.
[7] Gelosa P,Davide L,Fumagalli M,et al.Microglia is a Key Player in the Reduction of Stroke Damage Promoted by the New Antithrombotic Agent Ticagrelor[J].J Cereb Blood Flow Metab,2014,34(6):979-988.
[8] Malko P,Sharifah AM,Mcwilliam J,et al.TRPM2 Channel in microglia as a new player in neuroinflammation associated with a spectrum of central nervous system pathologies[J].Front Pharmacol,2019,10:239.
[9] Janicki PK,Eyileten C,Ruiz-Velasco VA,et al.Population-Specific associations of deleterious rare variants in coding region of P2RY1-P2RY12 purinergic receptor genes in Large-Vessel ischemic stroke patients[J].Int J Mol Sci,2017,18(12):2678.
[10] Francisco JR,Ilias K,Cedric G,et al.Beyond clotting: a role of platelets in CNS repair?[J].Front Cell Neurosci,2016,9:511.
[11] Nylander S,Schulz R.Effects of P2Y12receptor antagonists beyond platelet inhibition-comparison of ticagrelor with thienopyridines[J].Br J Pharmacol,2016,173(7):1163-1178.
[12] Maiocchi S,Alwis I,Wu MK,et al.Thromboinflammatory functions of platelets in ischemia-reperfusion injury and its dysregulation in diabetes[J].Semin Thromb Hemost,2018,44(2):102-113.
[13] Xuan N,Pi SL,Baral S,et al.P2Y 12 promotes migration of vascular smooth muscle cells through cofilin dephosphorylation during atherogenesis[J].Arterioscler Thromb Vasc Biol,2017,37(3):515-524.
[14] Hiroshi S,Nagata D,Takahashi M,et al.Involvement of P2Y12 receptor in vascular smooth muscle inflammatory changes via MCP-1 upregulation and monocyte adhesion[J].Am J Physiol Heart Circ Physiol,2015,308(8):H853-H861.
[15] Xu SW,Fu J,Chen JW,et al.Development of an optimized protocol for primary culture of smooth muscle cells from rat thoracic aortas[J].Cytotechnology,2009,61(1/2):65-72.
[16] Cotrina ML,Lou NH,Tome-Garcia J,et al.Direct comparison of microglial dynamics and inflammatory profile in photothrombotic and arterial occlusion evoked stroke[J].Neuroscience,2017,343:483-494.
[17] Zhao B,Zhao CZ,Zhang XY,et al.The new P2Y-like receptor G protein-coupled receptor 17 mediates acute neuronal injury and late microgliosis after focal cerebral ischemia in rats[J].Neuroscience,2012,202:42-57.
[18] Webster CM,Hokari M,Mcmanus A,et al.Microglial P2Y12 deficiency/inhibition protects against brain ischemia[J].PLoS One,2013,8(8):e70927.
[19] Nishioku T,Matsumoto J,Shinya D,et al.Tumor necrosis factor-α mediates the blood-brain barrier dysfunction induced by activated microglia in mouse brain microvascular endothelial cells[J].J Pharmacol Sci,2010,112(2):251-254.
[20] Shigemoto-Mogami Y,Hoshikawa K,Sato K.Activated microglia disrupt the Blood-Brain barrier and induce chemokines and cytokines in a rat in vitro model[J].Front Cell Neurosci,2018,12:494.
[21] Jolivel V,Bicker F,Binamé F,et al.Perivascular microglia promote blood vessel disintegration in the ischemic penumbra[J].Acta Neuropathol,2015,129(2):279-295.
[22] Kim TJ,Lee JS,Kang MK,et al.Clopidogrel May decrease the risk of post-stroke infection after ischaemic stroke[J].European Journal of Neurology,2019,26(2):261-267.
[23] Wang XL,Deng HF,Li T,et al.Clopidogrel reduces lipopolysaccharide-induced inflammation and neutrophil-platelet aggregates in an experimental endotoxemic model[J].J Biochem Mol Toxicol,2019,33(4):e22279.
[24] Thomas MR,Outteridge SN,Ramzi AA,et al.Platelet P2Y 12 inhibitors reduce systemic inflammation and its prothrombotic effects in an experimental human model[J].Arterioscler Thromb Vasc Biol,2015,35(12):2562-2570.
[25] Gurbel PA,Bliden KP,Tantry US.Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study[J].J Am Coll Cardiol,2006,48(11):2186-2191.
[26] Paruchuri S,Tashimo H,Feng C,et al.Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor[J].J Exp Med,2009,206(11):2543-2555.
[27] An XB,Jiang GN,Cheng C,et al.Inhibition of platelets by clopidogrel suppressed Ang II-induced vascular inflammation, oxidative stress, and remodeling[J].J Am Heart Assoc,2018,7(21):e009600.
[28] Diehl P,Christoph O,Christoph H,et al.Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes[J].Basic Res Cardiol,2010,105(3):379-387.
[29] Sugidachi A,Mizuno M,Ohno K,et al.The active metabolite of prasugrel, R-138727, improves cerebral blood flow and reduces cerebral infarction and neurologic deficits in a non-human Primate model of acute ischaemic stroke[J].Eur J Pharmacol,2016,788:132-139.
[30] Totani L,Dell'elba G,Martelli N,et al.Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse[J].Thromb Haemost,2012,107(6):1130-1140.
[31] Boulaftali Y,Owens AP,Beale A,et al.CalDAG-GEFI deficiency reduces atherosclerotic lesion development in mice[J].Arterioscler Thromb Vasc Biol,2016,36(5):792-799.
[32] Waltraud S,Kral J,Badrnya S,et al.Aspirin and P2Y12 inhibitors in platelet-mediated activation of neutrophils and monocytes[J].Thromb Haemost,2015,114(9):478-789.
[33] Ganbaatar B,Fukuda D,Salim HM,et al.Ticagrelor, a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice[J].Atherosclerosis,2018,275:124-132.
[34] Preusch MR,Rusnak J,Staudacher K,et al.Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis[J].Drug Des Devel Ther,2016,10:2691-2699.
[35] Steinhubl SR,Badimon JJ,Deepak LB,et al.Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease[J].Vascular Medicine,2007,12(2):113-122.
[36] West LE,Steiner T,Judge HM,et al.Vessel wall, not platelet, P2Y12 potentiates early atherogenesis[J].Cardiovasc Res,2014,102(3):429-435.
[37] Bernhard HR,Rosenkranz AC,Ermler S,et al.Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions[J].Arterioscler Thromb Vasc Biol,2010,30(12):2434-2442.
[38] Cheng-Hung L,Ming-Jer H,Liu KS,et al.Promoting vascular healing using nanofibrous ticagrelor-eluting stents[J].Int J Nanomedicine,2018,Volume 13:6039-6048.
[39] Trenk D,Hochholzer W.Genetics of platelet inhibitor treatment[J].Br J Clin Pharmacol,2014,77(4):642-653.
[40] Li XJ,Cai L,Zhu XX,et al.Evaluation of tolerability, pharmacokinetics and pharmacodynamics of vicagrel, a novel P2Y12 antagonist, in healthy Chinese volunteers[J].Front Pharmacol,2018,9:643.
[41] Högberg C,Svensson H,Gustafsson R,et al.The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature[J].Int J Cardiol,2010,142(2):187-192.
[42] Tsigkou V,Siasos G,Rovos K,et al.Peripheral artery disease and antiplatelet treatment[J].Curr Opin Pharmacol,2018,39:43-52.